[Molecular-based treatment concepts in advanced pancreatic cancer]

Dtsch Med Wochenschr. 2007 Apr 13;132(15):818-22. doi: 10.1055/s-2007-973627.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Cetuximab
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Farnesyltranstransferase / antagonists & inhibitors
  • Gemcitabine
  • Gene Expression Regulation, Neoplastic
  • Genes, ras / physiology
  • Humans
  • Metalloproteases / antagonists & inhibitors
  • Molecular Biology
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / metabolism
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Quinazolines
  • Vascular Endothelial Growth Factor A
  • Deoxycytidine
  • Bevacizumab
  • Erlotinib Hydrochloride
  • Farnesyltranstransferase
  • ErbB Receptors
  • Metalloproteases
  • Cetuximab
  • Gemcitabine